Carlos Bais
About
Carlos Bais is a scholar working on Oncology, Cancer Research and Molecular Biology.
According to data from OpenAlex, Carlos Bais has authored 38 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 15 papers in Cancer Research and 13 papers in Molecular Biology. Recurrent topics in Carlos Bais's work include Viral-associated cancers and disorders (6 papers), Cancer Genomics and Diagnostics (6 papers) and Cancer, Hypoxia, and Metabolism (5 papers). Carlos Bais is often cited by papers focused on Viral-associated cancers and disorders (6 papers), Cancer Genomics and Diagnostics (6 papers) and Cancer, Hypoxia, and Metabolism (5 papers). Carlos Bais collaborates with scholars based in United States, United Kingdom and Switzerland. Carlos Bais's co-authors include Enrique A. Mesri, J. Silvio Gutkind, Napoleone Ferrara, Jenny Yao, Ethel Cesarman, Leandros Arvanitakis, Xiumin Wu, Omar A. Coso, Iva Greenwald and Adam S. Asch and has published in prestigious journals such as Nature, Science and Cell.
In The Last Decade
Carlos Bais
37 papers receiving 4.0k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Carlos Bais United States | 20 | 1.9k | 1.9k | 1.0k | 967 | 603 | 38 | 4.1k | ||
| Bahija Jallal United States | 47 | 2.6k 1.4× | 1.3k 0.7× | 2.0k 2.0× | 634 0.7× | 837 1.4× | 86 | 5.5k | ||
| Todd VanArsdale United States | 27 | 1.7k 0.9× | 1.4k 0.8× | 1.0k 1.0× | 617 0.6× | 268 0.4× | 48 | 3.7k | ||
| A. Hunter Shain United States | 23 | 2.8k 1.4× | 2.1k 1.1× | 544 0.5× | 1.2k 1.3× | 288 0.5× | 36 | 4.6k | ||
| Christine M. Eischen United States | 44 | 5.0k 2.6× | 3.1k 1.6× | 1.1k 1.1× | 1.5k 1.5× | 356 0.6× | 99 | 6.8k | ||
| Tsutomu Kasugai Japan | 34 | 1.7k 0.9× | 1.2k 0.6× | 1.4k 1.4× | 1.0k 1.1× | 615 1.0× | 114 | 4.9k | ||
| Ferenc A. Scheeren Netherlands | 26 | 1.4k 0.7× | 1.2k 0.6× | 1.5k 1.5× | 596 0.6× | 253 0.4× | 49 | 3.4k | ||
| Pierre Cordelier France | 36 | 2.5k 1.3× | 1.9k 1.0× | 386 0.4× | 1.6k 1.7× | 583 1.0× | 104 | 4.5k | ||
| Akrit Sodhi United States | 33 | 1.7k 0.9× | 1.4k 0.8× | 532 0.5× | 740 0.8× | 711 1.2× | 64 | 4.3k | ||
| David A. Barbie United States | 30 | 2.7k 1.4× | 2.2k 1.2× | 1.4k 1.4× | 628 0.6× | 247 0.4× | 81 | 5.0k | ||
| Bjørn Risberg Norway | 41 | 1.8k 0.9× | 1.4k 0.7× | 556 0.6× | 877 0.9× | 456 0.8× | 131 | 4.6k |
Countries citing papers authored by Carlos Bais
Since
Specialization
Citations
This map shows the geographic impact of Carlos Bais's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carlos Bais with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carlos Bais more than expected).
Fields of papers citing papers by Carlos Bais
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Carlos Bais. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carlos Bais. The network helps show where Carlos Bais may publish in the future.
Co-authorship network of co-authors of Carlos Bais
This figure shows the co-authorship network connecting the top 25 collaborators of Carlos Bais. A scholar is included among the top collaborators of Carlos Bais based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carlos Bais. Carlos Bais is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Qu, Xueping, Habib Hamidi, Radia Marie Johnson, et al.. (2025). Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer. Nature Communications. 16(1). 4332–4332.
2.
Johnson, Radia Marie, Xueping Qu, Ling‐Yuh Huw, et al.. (2022). ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer. Nature Communications. 13(1). 5478–5478.
3.
Daemen, Anneleen, Thomas Sandmann, Congfen Li, et al.. (2021). Transcriptomic profiling of adjuvant colorectal cancer identifies three key prognostic biological processes and a disease specific role for granzyme B. PLoS ONE. 16(12). e0262198–e0262198.
4.
Johnson, Radia Marie, Heidi Phillips, Carlos Bais, et al.. (2020). Development of a gene expression–based prognostic signature for IDH wild-type glioblastoma. Neuro-Oncology. 22(12). 1742–1756.
5.
Desbois, Mélanie, Akshata R. Udyavar, Lisa Ryner, et al.. (2020). Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer. Nature Communications. 11(1). 5583–5583.
6.
Raja, Rajiv, Young S. Lee, Katie Streicher, et al.. (2017). Integrating Genomics into Drug Discovery and Development: Challenges and Aspirations. Pharmaceutical Medicine. 31(4). 217–233.
7.
Miles, David, David Cameron, Igor Bondarenko, et al.. (2016). Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation. European Journal of Cancer. 70. 146–155.
8.
Ryner, Lisa, Yinghui Guan, Ron Firestein, et al.. (2015). Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer. Clinical Cancer Research. 21(13). 2941–2951.
9.
Sandmann, Thomas, Richard Bourgon, Josep Garcia, et al.. (2015). Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. Journal of Clinical Oncology. 33(25). 2735–2744.
10.
Birrer, Michael J., YounJeong Choi, Mark F. Brady, et al.. (2015). Retrospective analysis of candidate predictive tumor biomarkers (BMs) for efficacy in the GOG-0218 trial evaluating front-line carboplatin–paclitaxel (CP) ± bevacizumab (BEV) for epithelial ovarian cancer (EOC).. Journal of Clinical Oncology. 33(15_suppl). 5505–5505.
11.
Croci, Diego O., Juan P. Cerliani, Tomás Dalotto‐Moreno, et al.. (2014). Glycosylation-Dependent Lectin-Receptor Interactions Preserve Angiogenesis in Anti-VEGF Refractory Tumors. Cell. 156(4). 744–758.
12.
Zhuang, Guanglei, Kebing Yu, Zhaoshi Jiang, et al.. (2013). Phosphoproteomic Analysis Implicates the mTORC2-FoxO1 Axis in VEGF Signaling and Feedback Activation of Receptor Tyrosine Kinases. Science Signaling. 6(271). ra25–ra25.
13.
Zhuang, Guanglei, Xiumin Wu, Zhaoshi Jiang, et al.. (2012). Tumour‐secreted miR‐9 promotes endothelial cell migration and angiogenesis by activating the JAK‐STAT pathway. The EMBO Journal. 31(17). 3513–3523.
14.
Yao, Jenny, Xiumin Wu, Guanglei Zhuang, et al.. (2011). Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy. Proceedings of the National Academy of Sciences. 108(28). 11590–11595.
15.
Yoo, Andrew S., Carlos Bais, & Iva Greenwald. (2004). Crosstalk Between the EGFR and LIN-12/Notch Pathways in C. elegans Vulval Development. Science. 303(5658). 663–666.
16.
Bais, Carlos, Albert Van Geelen, Pîlar Eroles, et al.. (2003). Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/ KDR. Cancer Cell. 3(2). 131–143.
17.
Sodhi, Akrit, Silvia Montaner, V. Patel, et al.. (2000). The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha.. PubMed. 60(17). 4873–80.
18.
Bais, Carlos, Bianca Santomasso, Omar A. Coso, et al.. (1998). G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature. 392(6672). 210–210.
19.
Geras‐Raaka, Elizabeth, Leandros Arvanitakis, Carlos Bais, et al.. (1998). Inhibition of Constitutive Signaling of Kaposi's Sarcoma–associated Herpesvirus G Protein–Coupled Receptor by Protein Kinases in Mammalian Cells in Culture. The Journal of Experimental Medicine. 187(5). 801–806.
20.
Bais, Carlos, Bianca Santomasso, Omar A. Coso, et al.. (1998). G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature. 391(6662). 86–89.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Bahija Jallal Breakdown of academic impact, for papers by Todd VanArsdale Breakdown of academic impact, for papers by A. Hunter Shain Breakdown of academic impact, for papers by Christine M. Eischen Breakdown of academic impact, for papers by Tsutomu Kasugai Breakdown of academic impact, for papers by Ferenc A. Scheeren Breakdown of academic impact, for papers by Pierre Cordelier Breakdown of academic impact, for papers by Akrit Sodhi Breakdown of academic impact, for papers by David A. Barbie Breakdown of academic impact, for papers by Bjørn Risberg